Literature DB >> 21773886

Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies.

Zeshan Ahmed1, Karen M Doherty, Laura Silveira-Moriyama, Rina Bandopadhyay, Tammaryn Lashley, Adamantios Mamais, Geshanthi Hondhamuni, Selina Wray, Jia Newcombe, Sean S O'Sullivan, Stephen Wroe, Rohan de Silva, Janice L Holton, Andrew J Lees, Tamas Revesz.   

Abstract

A number of recent studies have described cases with tau-positive globular oligodendroglial inclusions (GOIs) and such cases have overlapping pathological features with progressive supranuclear palsy (PSP), but present with clinical features of motor neuron disease (MND) and/or frontotemporal dementia (FTD). These two clinical phenotypes have been published independently and as a result, have come to be considered as distinct disease entities. We describe the clinicopathological and biochemical features of two cases with GOIs: one with clinical symptoms suggestive of MND and the other with FTD. Histological changes in our two cases were consistent with their clinical symptoms; the MND case had severe neurodegeneration in the primary motor cortex and corticospinal tract, whereas the FTD case had severe involvement of the frontotemporal cortices and associated white matter. Immunohistochemistry in both cases revealed significant 4-repeat (4R) tau pathology primarily in the form of GOIs, but also in astrocytes and neurons. Astrocytic tau pathology was morphologically similar to that seen in PSP, but in contrast was consistently negative for Gallyas silver staining. Tau-specific western blotting revealed 68, 64 and 35 kDa bands, showing further overlap with PSP. The underlying neuropathological features of these two cases were similar, with the major difference relating to the regional distribution of pathology and resulting clinical symptoms and signs. The globular nature of glial inclusions and the non-fibrillar properties of tau in astrocytes are characteristic features that allow them to be distinguished from PSP and other tauopathies. We, therefore, propose the term globular glial tauopathy as an encompassing term to classify this emerging class of 4R tauopathy.

Entities:  

Mesh:

Year:  2011        PMID: 21773886     DOI: 10.1007/s00401-011-0857-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  25 in total

1.  Globular glial tauopathies (GGT): consensus recommendations.

Authors:  Zeshan Ahmed; Gabor G Kovacs; Eileen H Bigio; Herbert Budka; Dennis W Dickson; Isidro Ferrer; Bernardino Ghetti; Giorgio Giaccone; Kimmo J Hatanpaa; Janice L Holton; Keith A Josephs; James Powers; Salvatore Spina; Hitoshi Takahashi; Charles L White; Tamas Revesz
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

2.  A novel tau mutation, p.K317N, causes globular glial tauopathy.

Authors:  Pawel Tacik; Michael DeTure; Wen-Lang Lin; Monica Sanchez Contreras; Aleksandra Wojtas; Kelly M Hinkle; Shinsuke Fujioka; Matthew C Baker; Ronald L Walton; Yari Carlomagno; Patricia H Brown; Audrey J Strongosky; Naomi Kouri; Melissa E Murray; Leonard Petrucelli; Keith A Josephs; Rosa Rademakers; Owen A Ross; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2015-04-22       Impact factor: 17.088

3.  Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy.

Authors:  P Tacik; M Sanchez-Contreras; M DeTure; M E Murray; R Rademakers; O A Ross; Z K Wszolek; J E Parisi; D S Knopman; R C Petersen; D W Dickson
Journal:  Neuropathol Appl Neurobiol       Date:  2017-03-08       Impact factor: 8.090

4.  Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings.

Authors:  M E Erro; M V Zelaya; M Mendioroz; R Larumbe; S Ortega-Cubero; J L Lanciego; A Lladó; T Cabada; T Tuñón; F García-Bragado; M R Luquin; P Pastor; I Ferrer
Journal:  J Neurol       Date:  2019-06-12       Impact factor: 4.849

5.  Progressive supranuclear palsy and primary lateral sclerosis secondary to globular glial tauopathy: a case report and a practical theoretical framework for the clinical prediction of this rare pathological entity.

Authors:  Andy J Liu; Jessica E Chang; Georges Naasan; Adam L Boxer; Bruce L Miller; Salvatore Spina
Journal:  Neurocase       Date:  2020-02-23       Impact factor: 0.881

6.  Corticobasal degeneration with olivopontocerebellar atrophy and TDP-43 pathology: an unusual clinicopathologic variant of CBD.

Authors:  Naomi Kouri; Kenichi Oshima; Makio Takahashi; Melissa E Murray; Zeshan Ahmed; Joseph E Parisi; Shu-Hui C Yen; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2013-01-31       Impact factor: 17.088

7.  Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation.

Authors:  Lea Tenenholz Grinberg; Xuehua Wang; Chao Wang; Peter Dongmin Sohn; Panos Theofilas; Manu Sidhu; John Benjamin Arevalo; Helmut Heinsen; Eric J Huang; Howard Rosen; Bruce L Miller; Li Gan; William W Seeley
Journal:  Acta Neuropathol       Date:  2013-01-31       Impact factor: 17.088

8.  A familial form of parkinsonism, dementia, and motor neuron disease: a longitudinal study.

Authors:  Shinsuke Fujioka; Bradley F Boeve; Joseph E Parisi; Pawel Tacik; Naoya Aoki; Audrey J Strongosky; Matt Baker; Monica Sanchez-Contreras; Owen A Ross; Rosa Rademakers; Vesna Sossi; Dennis W Dickson; A Jon Stoessl; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2014-08-19       Impact factor: 4.891

Review 9.  Development of disease-modifying drugs for frontotemporal dementia spectrum disorders.

Authors:  Francesco Panza; Bruno P Imbimbo; Madia Lozupone; Davide Seripa; Antonio Daniele; Mark Watling; Gianluigi Giannelli
Journal:  Nat Rev Neurol       Date:  2020-03-23       Impact factor: 42.937

10.  A case of globular glial tauopathy presenting clinically as alzheimer disease.

Authors:  Karen S SantaCruz; Sue J Rottunda; Joyce P Meints; Elaine L Bearer; Eileen H Bigio; John Riley McCarten
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jan-Mar       Impact factor: 2.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.